Answer:I think they would die from not doing anything.
Answer:
If it is tested in a controlled setting with repeated results
Explanation:
Answer:
E) Either anaphase I or II
Explanation:
Failure of segregation of homologous chromosomes during anaphase I or failure of segregation of sister chromatids during anaphase II leads to the presence of the abnormal number of chromosomes in resultant gametes. In the given example, the egg mother cell with 48 chromosomes (24 pairs) would enter meiosis I but the failure of one pair of homologous chromosomes to segregate from each other followed by normal meiosis II would result in the formation of two gametes with one extra chromosome and two gametes with one less chromosome.
On the other hand, if the nondisjunction occurs at anaphase II of meiosis II, two normal gametes, one gamete with one extra chromosome and one gamete with one less chromosome will be formed. Therefore, nondisjunction at anaphase I or anaphase II would have resulted in the production of eggs with one extra chromosome.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
